Antibiotic resistance in Staphylococcus aureus and its relevance in therapy

被引：47

作者：

Bal, AM ^{[1
]}

Gould, IM ^{[1
]}

机构：

[1] Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2005年 / 6卷 / 13期

关键词：

D O I：

10.1517/14656566.6.13.2257

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Staphylococcus aureus is a major cause of infections. Only similar to 20% of the strains remain sensitive to penicillin. P-lactamase stable penicillins such as flucloxacillin form the mainstay of treatment of staphylococcal infection. Meticillin-resistant S. aureus (MRSA) are resistant to all P-lactam antibiotics. Glycopepticle antibiotics are effective against most MRSA strains but, in the last few years, isolates of MRSA that have reduced susceptibility to glycopepticles (glycopepticle-intermediate S. aureus) have been isolated. Some strains exhibit frank resistance to glycopepticles (vancomycin-resistant S. aureus). infections due to these strains are difficult to treat. This review summarises the therapeutic options for MRSA, glycopepticle-intermediate S. aureus and vancomycin-resistant S. aureus. Novel therapeutic strategies such as immunotherapy and vaccines are also discussed.

引用

页码：2257 / 2269

页数：13

共 128 条

[1] Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs [J].

Abramson, MA ;

Sexton, DJ .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) :408-411

[2] Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections [J].

Adra, M ;

Lawrence, KR .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (02) :338-341

[3] Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model [J].

Aeschlimann, JR ;

Allen, GP ;

Hershberger, E ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :2991-2998

[4] Mechanism of action of oritavancin and related glycopeptide antibiotics [J].

Allen, NE ;

Nicas, TI .

FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532

[5] NUCLEOTIDE-SEQUENCE OF A STAPHYLOCOCCAL PLASMID GENE, VGB, ENCODING A HYDROLASE INACTIVATING THE B-COMPONENTS OF VIRGINIAMYCIN-LIKE ANTIBIOTICS [J].

ALLIGNET, J ;

LONCLE, V ;

MAZODIER, P ;

ELSOLH, N .

PLASMID, 1988, 20 (03) :271-275

[6] Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA):: successful treatment with linezolid in combination with intraventricular vancomycin [J].

Amod, F ;

Moodley, I ;

Peer, AKC ;

Sunderland, J ;

Lovering, A ;

Wootton, M ;

Nadvi, S ;

Vawda, F .

JOURNAL OF INFECTION, 2005, 50 (03) :252-257

[7] Endocarditis due to glycopeptide-intermediate Staphylococcus aureus:: case report and strain characterization [J].

Andrade-Baiocchi, S ;

Tognim, MCB ;

Baiocchi, OCG ;

Sader, HS .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (02) :149-152

[8]

[Anonymous], 2005, PRINCIPLES PRACTICE

[9] In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci [J].

Auckenthaler, R ;

Courvalin, P ;

Féger, C ;

Roche, G .

CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (11) :608-612

[10] Genome and virulence determinants of high virulence community-acquired MRSA [J].

Baba, T ;

Takeuchi, F ;

Kuroda, M ;

Yuzawa, H ;

Aoki, K ;

Oguchi, A ;

Nagai, Y ;

Iwama, N ;

Asano, K ;

Naimi, T ;

Kuroda, H ;

Cui, L ;

Yamamoto, K ;

Hiramatsu, K .

LANCET, 2002, 359 (9320) :1819-1827

← 1 2 3 4 5 6 7 8 9 10 →